Skip to main content
. Author manuscript; available in PMC: 2022 May 29.
Published in final edited form as: Pancreatology. 2020 Jul 25;20(6):1109–1114. doi: 10.1016/j.pan.2020.07.396

Table 4:

Comparison of cumulative prevalence of fragility fracture in NAPS2 CP patients from UPMC with controls in two published US studies

NAPS-2 CP
patients
N (%)# 		Tignor et al. 2010
Control Subjects
N (%)		 Munigala et al. 2016
Control Subjects
N (%)
Total subjects 22/227 (9.69) 11486/785556 (1.46) 7097/328983 (2.16)
Males
  45-65 years 7/86 (8.13) 1724/170520 (1.01) 4064/199745 (2.03)
  > 65 years 4/41 (9.75) 2036/133797 (1.52) 2528/104453 (2.42)
Females
  45-65 years 5/62 (8.06) 2599/303266 (0.86) 330/20260 (1.63)
  > 65 years 6/38 (15.79) 5127/177973 (2.88) 175/4525 (3.87)
#

Only patients ≥ 45 years at last contact were included in this analysis

All p-values are ≤0.001 for all comparisons between NAPS2 CP patients vs. controls